Axogen, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Axogen, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-0.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 64% of Healthcare companies in United States.
Cash Locked Ratio
$29For every $100 of sales, $29 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $23 tied up three years earlier.
More money tied up than 63% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$15Sales grew 63% in 3 years; of every extra $100 of sales, $15 became extra profit.
Lower than 55% of Healthcare companies in United States.
Asset Productivity Ratio
+63% / +13%In 3 years sales changed by +63% while total assets changed by +13%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
0.3×Debt due within a year is covered 0.3 times by its yearly operating cash.
Higher than 69% of Healthcare companies in United States.
Cash Cushion Ratio
−1%Debt, after subtracting cash, equals 1% of its market value (net debt).
Lower than 69% of Healthcare companies in United States.
Tangible Assets Ratio
97%Of every $100 the company owns, $97 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 80% of Healthcare companies in United States.
Tangible Net Worth Ratio
95%Of every $100 of net worth, $95 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 80% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Axogen, Inc. made a loss over the last year. Axogen, Inc. owes $0.16 for every $1 it owns. Axogen, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAxogen, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
8.40The share price is 8.40 times Axogen, Inc.'s book value per share, higher than 84% of Healthcare companies in United States.
Market cap
$2.2 BThe total market value of all of Axogen, Inc.'s shares at today's price (share price × number of shares), larger than 76% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$256 MWhat Axogen, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.37Net worth divided by the number of shares. The share price of $36.68 is 8.4 times this, which is the P/B above.
Return on equity (ROE)
-18.2%Axogen, Inc. lost 18.2% of its shareholders' money over the last year, higher than 67% of Healthcare companies in United States.
Owes vs Owns
0.16×Axogen, Inc. owes $0.16 for every $1 it owns (low), lower than 79% of Healthcare companies in United States.
Dividend yield
NoneAxogen, Inc. does not currently pay a dividend.
Revenue growth
+20%Revenue rose 20% in the year to Dec 2025, and grew 18% a year on average over 3 years.
Profit growth
LossAxogen, Inc. made a loss in each of the last two years.
Profit margin
-7.0%Axogen, Inc. lost $7 for every $100 of revenue.
Interest cover
Not coveredAxogen, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtAxogen, Inc. had $26 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Axogen, Inc.: $2.2 B ÷ $256 M (30 Jun 2026) = 8.4.
What is Axogen, Inc.'s return on equity?
Axogen, Inc. lost 18.2% of its shareholders' money over the last year, higher than 67% of Healthcare companies in United States.
How much does Axogen, Inc. owe compared with what it owns?
Axogen, Inc. owes $0.16 for every $1 it owns (low), lower than 79% of Healthcare companies in United States.
Does Axogen, Inc. pay a dividend?
No. Axogen, Inc. does not currently pay a dividend.
Is Axogen, Inc.'s revenue growing?
Revenue rose 20% in the year to Dec 2025, and grew 18% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.